Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Aktis Oncology (NASDAQ: AKTS) closed an upsized initial public offering of 17,650,000 shares at $18.00 per share on January 12, 2026, and the underwriters fully exercised an option to purchase an additional 2,647,500 shares at the same price, with that sale expected to close on January 14, 2026, subject to customary conditions.
The aggregate gross proceeds including the overallotment are expected to be approximately $365.4 million before underwriting discounts, commissions and offering expenses. Aktis began trading on the Nasdaq Global Select Market on January 9, 2026 under the ticker AKTS.
Vida Ventures applauded Aktis Oncology (Nasdaq: AKTS) on entering the public markets after an IPO that raised $318 million. Vida said it co-led Aktis’ Series A, remained a long‑term investor and was the company’s second‑largest shareholder pre‑IPO, with Helen Kim serving on the Aktis board since 2021. Vida co‑founder Brian Goodman served as Aktis’ founding COO and later CBO. Vida highlighted Aktis’ pipeline led by AKY-1189 (actinium-225, Nectin-4) and AKY-2519 (B7-H3), prior private funding of approximately $346 million, and a strategic collaboration with Eli Lilly that Vida described as a deal valued up to $1.2 billion.
Akoustis Technologies (NASDAQ: AKTS), a manufacturer of BAW high-band RF filters, has voluntarily filed for Chapter 11 bankruptcy protection in Delaware following a $59 million legal judgment against the company in favor of Qorvo, Inc. The judgment includes damages, fees, and interest related to trade secret misappropriation and patent infringement claims.
The company has entered into a stalking horse asset purchase agreement with Gordon Brothers Commercial & Industrial, and will pursue a court-supervised sale process to seek the highest bid for its assets. Akoustis states it has sufficient liquidity to maintain normal operations during this process and has filed 'first day' motions to ensure continued employee wages, benefits, and critical vendor payments.
Akoustis Technologies (NASDAQ: AKTS) has received an additional $13 million purchase order for XBAW® filters from an existing Tier-1 customer, bringing total production commitments to over $21 million. The order is for seven Wi-Fi Access Point (AP) production programs, with an option for the customer to increase quantities based on demand.
This order strengthens Akoustis' relationship with the Tier-1 Wi-Fi AP customer, whose architecture aligns well with Akoustis' advanced filter capabilities. The company plans to deliver several million units over the next 3-4 quarters, supporting both Wi-Fi 6E and new Wi-Fi 7 platforms. The order includes ten unique XBAW® filters, with six next-generation designs offering improved performance in a smaller form factor at a lower cost.
Akoustis Technologies, Inc. (Nasdaq: AKTS) announced a significant leadership transition on August 8, 2024. Jeffery B. Shealy has mutually agreed to resign as Chief Executive Officer and Board member, effective August 6, 2024. Kamran Cheema, the company's Chief Product Officer since 2022, will serve as interim CEO. Mr. Cheema, who joined Akoustis in August 2021 as VP of Engineering, brings over 30 years of experience in acoustic technology and RF expertise.
Prior to Akoustis, Mr. Cheema was Vice President of Engineering at Qualcomm RF360, overseeing micro-acoustic hardware solutions for the mobile phone market. The Board of Directors, through co-chairman Arthur Geiss, expressed gratitude for Mr. Shealy's years of service and leadership, wishing him well in his future endeavors.
Akoustis announced securing $8 million in orders from a Tier-1 customer for its patented XBAW® filters. These filters will be used in Wi-Fi 6E and Wi-Fi 7 Access Points (APs), with deliveries planned through fiscal year 2025. The company will support the customer's demand with four existing and two new Wi-Fi 7 programs. The orders include ten unique filter designs, aimed at enhancing performance and offering a lower cost platform. This collaboration solidifies Akoustis' role as a key supplier in the Wi-Fi market.
Akoustis Technologies (NASDAQ: AKTS) has secured $2 million in volume orders from a Tier-1 carrier for its next-generation 5.5 and 6.5 GHz Wi-Fi XBAW® filters. These filters will be integrated into a Wi-Fi 7 platform and support production from July 2024 to March 2025. The company anticipates record revenue in the September quarter due to strong demand for Wi-Fi 6E and Wi-Fi 7 programs. The new orders reflect the growing need for high-speed connectivity in residential, small, and medium-sized business environments. Akoustis aims to announce additional production orders in the coming weeks.
Akoustis Technologies (Nasdaq: AKTS), a producer of high-band RF filters, announced a $10 million registered direct offering. This involves the sale of 50,000,000 shares at $0.20 each. Expected to close on May 24, 2024, the offering adheres to Nasdaq rules and will be handled by Roth Capital Partners. Gross proceeds are estimated at $10 million before fees. The funds will be used for working capital and operations. The offering is based on a previously filed and effective Form S-3 registration with the SEC. Interested parties can obtain prospectus details from the SEC or Roth Capital Partners.
Akoustis Technologies (NASDAQ: AKTS) announced the successful rollout of design updates to its XBAW® RF filters, aiming to remove patented features claimed by Qorvo. These updates respond to the legal verdict in Qorvo, Inc. vs. Akoustis Technologies, Inc., and have been incorporated into new and existing products since Fall 2022. Despite the jury’s verdict, Akoustis asserts that the design changes do not affect the performance or reliability of its products. The company is prepared for any potential injunctions and plans to continue marketing its product portfolio effectively.
Akoustis Technologies, Inc. reported third-quarter results with a 7% increase in revenue quarter-over-quarter, along with a 13% growth in filter-related revenue. The company anticipates breakeven operating cash flow in the next nine months due to cost-saving initiatives. Akoustis continues to secure design wins in various markets like Wi-Fi, 5G Infrastructure, Automotive, and Defense, projecting robust customer activity and revenue growth.